Clinical Trial Update: Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update on cabozantinib (XL184) for advanced medullary thyroid cancer provides efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• XL184 (cabozantinib)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Thyroid Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-09-09